ChinaNet (CNET) Raises 2012 Net Income Guidance to $3.1 Million

BEIJING, Oct. 11, 2012 (GLOBE NEWSWIRE) — ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (the “Company”), a leading B2B (business to business) Internet technology company focusing on providing online-to-offline (“O2O”) sales channel expansion services for small and medium-sized enterprises (“SMEs”) and entrepreneurial management and networking services for entrepreneurs in the People’s Republic of China, today announced that the Company is raising its 2012 full year net income guidance to $3.1 million from $2.8 million previously provided. The revised net income guidance does not include any benefits from the proposed acquisition of the remaining 49% equity interest in Sou Yi Lian Mei Network Technology (“SouYi”) announced on September 17, 2012.

“We have taken aggressive actions to improve our margins,” stated Mr. George Chu, COO of ChinaNet. “The increase in our net income guidance reflects both improved expense management as well as a better than expected recovery from 28.com, and growth from Liansuo.com and brand management services and solutions based on our cloud-based marketing platform. As we introduce these services to a wider audience, our new web portals are gaining more and more recognition from larger sized small businesses. With the integration of SouYi, we are able to clearly divide existing and potential clients into segments for better services and higher revenue. In addition, since we initiated a cost management plan at the beginning of the year, we have started to see some rewards from this plan. However, we will not slow our talent recruitment or technology development as they will further differentiate ChinaNet from other competitors. Overall, we expect the gradual recovery in China’s economy to benefit our core small business customers.”

About ChinaNet Online Holdings, Inc.

The Company, a parent company of ChinaNet Online Media Group Ltd., incorporated in the BVI (“ChinaNet”), is a leading B2B (business to business) Internet technology company focusing on providing O2O (online to offline) sales channel expansion service for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking service for entrepreneurs in China. The Company, through certain contractual arrangements with operating companies in the PRC, provides Internet advertising and other services for Chinese SMEs via its portal websites, 28.com, Liansuo.com and Chuangye.com, TV commercials and program production via China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. Website: http://www.chinanet-online.com.

Safe Harbor

This release contains certain “forward-looking statements” relating to the business of ChinaNet Online Holdings, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ChinaNet’s current expectations and beliefs concerning future developments and their potential effects on the company. There can be no assurance that future developments affecting ChinaNet will be those anticipated by ChinaNet. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ChinaNet undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: MZ North America
         Ted Haberfield, President
         Tel: +1-760-755-2716
         Email: thaberfield@mzgroup.us
         Web: www.mzgroup.us

Keegan (KGN) Provides Revised Resource Estimate For Esaase Gold Project

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 10/10/12 — Keegan Resources Inc. (TSX:KGN)(NYSE MKT:KGN)(NYSE Amex:KGN) (“Keegan” or the “Company”) is pleased to announce the results of a revised mineral resource estimate for its Esaase gold project in Ghana, West Africa. The resource estimate is based upon approximately 200,000 metres of RC drilling and 78,000 metres of diamond drilling carried out over the past five years at Esaase. The revised Esaase mineral resource estimate consists of:

--  Measured and Indicated resource of 68.92 million tonnes averaging 1.73
    grams per tonne gold for 3.83 million ounces, and
--  Inferred resource of 22.23 million tonnes averaging 1.75 grams per tonne
    gold for 1.25 million ounces.

The revised resource estimate, based on a cut-off grade of 0.8 grams per tonne of gold, was prepared using the same information used to compile the previous resource estimate at Esaase (see news release with Pre Feasibility Study results dated September 22, 2011 at www.keeganresources.com) which was stated at a cut-off of 0.4 grams per tonne of gold. The purpose of revising the resource was to serve as a basis for a revised Pre Feasibility Study (“PFS”) which will incorporate a change in open-pit mining methods to selectively mine at lower rates and higher grades than the September 2011 PFS.

Shawn Wallace, President and Chief Executive Officer of Keegan, said, “We are very pleased with this positive step forward. The revised resource validates the approach that, after much consideration, we have undertaken in re-engineering the Esaase project. The deposit, like many Ghanaian gold deposits, lends itself to selective mining and the mine plan for the revised PFS will feature a significantly higher mill feed grade than our previous mine plan. With a capital cost for the project of approximately $260 million and our cash balance of $188 million, we are well positioned to rapidly move forward and advance the Esaase project to production.

“We are looking forward to the results of our revised PFS which will be complete in early 2013. The company has also initiated efforts to recruit a multidisciplinary suite of individuals to help strengthen our team with the requisite experience in mine building and operation for the rapid development of a highly profitable new gold mine in Ghana, the most desirable location in West Africa.”

The mineral resource estimate was completed by Minxcon Pty Ltd. (“Minxcon”) of Johannesburg, South Africa and reported in accordance with National Instrument 43-101 requirements and the South African Code for Reporting of Exploration Results (SAMREC) which is consistent with the CIM Estimation Best Practice Guidelines in Canada. The resource estimate was prepared by Charles J. Muller, B.Sc. Geology (Hons), Pr.Sci.Nat., MGSSA, a Director of Minxcon. An updated NI 43-101 Technical Report will be filed on SEDAR at www.sedar.com on or before November 23, 2012.

A preliminary open pit optimization was run on the estimated grade model to support the requirement that Mineral Resources have reasonable prospects for economic extraction. The resource estimate assumes a long-term gold price of $1,150 per ounce, consistent with the gold price assumption made in the September 2011 PFS. All production and technical parameters assumed for the revised estimate were based on work completed by DRA, a Johannesburg based engineering consultant, as part of a Conceptual Study completed in August 2012 and outlined in a news release dated September 6, 2012 available at www.keeganresources.com.

The table below represents the mineral resource at the 0.8 grams of gold per tonne cut-off as well as at several additional cut-off grades which are provided for comparison purposes. The effective date of the resource is October 10, 2012 and the resource includes all drill results as at March 31, 2012.

--------------------------------------------------------------
                                            Gold          Gold
Cut-Off     Resource            Tonnes     Grade        Ounces
Au g/t      Category              (Mt)     (g/t)         (Moz)
--------------------------------------------------------------
0.4         Measured             30.14      1.27          1.23
            --------------------------------------------------
            Indicated            98.99      1.17          3.73
            --------------------------------------------------
               Total M&I        129.13      1.19          4.96
            --------------------------------------------------
            Inferred             49.39      1.11          1.76
--------------------------------------------------------------
0.6         Measured             23.38      1.49          1.12
            --------------------------------------------------
            Indicated            71.25      1.44          3.29
            --------------------------------------------------
               Total M&I         94.63      1.45          4.41
            --------------------------------------------------
            Inferred             33.59      1.40          1.51
--------------------------------------------------------------
0.8         Measured             17.52      1.75          0.99
            --------------------------------------------------
            Indicated            51.40      1.72          2.85
            --------------------------------------------------
               Total M&I         68.92      1.73          3.83
            --------------------------------------------------
            Inferred             22.23      1.75          1.25
--------------------------------------------------------------
1.0         Measured             12.96      2.05          0.86
            --------------------------------------------------
            Indicated            37.60      2.02          2.44
            --------------------------------------------------
               Total M&I         50.56      2.03          3.30
            --------------------------------------------------
            Inferred             16.00      2.09          1.08
--------------------------------------------------------------
NOTE: Due to rounding differences, some M&I totals may not add exactly with
the Measured and Indicated figures.

On Behalf of the Board of Directors,

Shawn Wallace, Chief Executive Officer

About Keegan Resources Inc.

Keegan is a junior gold company offering investors the opportunity to share ownership in the rapid exploration and development of high quality pure gold assets. The Company is focused on its wholly owned flagship Esaase Gold Project (3.83 million ounces of gold in the Measured and Indicated category with an average grade of 1.73 g/t Au and 1.25 million ounces of gold in the Inferred category at an average grade of 1.75 g/t Au, based on a 0.8 g/t Au cut-off) located in Ghana, West Africa; a highly favourable and prospective jurisdiction. Managed by highly skilled and successful technical and financial professionals, Keegan is well financed with no debt. Keegan is also strongly committed to the highest standards for environmental management, social responsibility, and health and safety for its employees and neighbouring communities.

Keegan trades on the TSX and the NYSE MKT under the symbol KGN.

More information about Keegan is available at www.keeganresources.com.

Qualified Person

The resource estimate was prepared by Charles J. Muller, B.Sc. Geology (Hons), Pr.Sci.Nat., MGSSA, a Director of Minxcon Pty Ltd. of Johannesburg, South Africa and an independent qualified person under NI 43-101, including the verification of the data disclosed, and the review and approval of the contents of this release. Richard Haslinger, P. Eng. Vice President Exploration for Keegan, a qualified person with respect to NI 43-101, has supervised the scientific or technical information for the Esaase property.

CIM Definition Standards were followed for Mineral Resources. Mineral Resources are reported on a 100% basis; Keegan has a 90% interest in this project with the Ghanaian Government owning a standard 10% free-carried interest.

Forward Looking and other Cautionary Information

This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address estimated resource quantities, grades and contained metals, possible future mining, exploration and development activities, are forward-looking statements. Although the Company believes the forward-looking statements are based on reasonable assumptions, such statements should not be in any way construed as guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices for metals, the conclusions of detailed feasibility and technical analyses, lower than expected grades and quantities of resources, mining rates and recovery rates and the lack of availability of necessary capital, which may not be available to the Company on terms acceptable to it or at all. The Company is subject to the specific risks inherent in the mining business as well as general economic and business conditions. For more information on the Company, Investors should review the Company’s annual Form 20-F filing with the United States Securities Commission and its home jurisdiction filings that are available at www.sedar.com.

Neither Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Keegan Resources Inc.
1.604.683.8193 or Toll Free: 1.800.863.8655
1.604.683.8194 (FAX)
info@keeganresources.com

Inovio Pharmaceuticals’ Cancer Vaccine Demonstrates Ability to Kill Target Cells

Inovio Pharmaceuticals’ Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells

— Article in Peer-Reviewed Science-Translational Medicine Reports Strong and Durable T Cell Responses from VGX-3100, Which is Designed to Treat Cervical Dysplasias Caused by HPV Infection — On-going phase II efficacy study will determine vaccine’s ability to reverse disease progression to cervical cancer

BLUE BELL, Pa., Oct. 10, 2012 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today clinical results indicating that its VGX-3100 therapeutic synthetic vaccine is capable of not only driving robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses displayed a powerful killing effect on cells changed by HPV into precancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia and cervical cancer. Inovio is currently assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial.

Results from this phase I trial appeared today in the peer-reviewed journal, Science-Translational Medicine, in an article entitled, “Immunotherapy against HPV 16/18 generates potent Th1 and cytotoxic cellular immune responses.”

The paper reports that 100% of patients (18 of 18) enrolled in the phase I dose-escalating trial showed antigen-specific antibody responses to Inovio’s vaccine, while 78% showed T-cell responses in the validated ELISpot assay. Further tests of T-cell immunity measured the ability of CD8+ T-cells from vaccinated patients to kill cells displaying HPV antigens on their surface: 91% of patients who developed T-cell responses showed the presence of CD8+ T-cells capable of this type of killing activity (so-called “killer T-cells”), which is believed to be critical for the treatment of cervical dysplasia and ultimately cancer caused by HPV.

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “Today’s milestone is convincing evidence that a DNA-based immune therapy can generate potent and durable T-cell responses in people. Our ongoing phase II efficacy trial is designed to show that the immune responses seen in this study, in particular the generation of killer T-cell responses, may reverse cervical disease caused by chronic HPV infection.”

“The type of T-cell killing activity seen in this new data provides a growing foundation for efficacy trials focused on the treatment of HPV-associated cancers including cervical, head and neck, and anogenital cancers,” Dr. Kim added.

Scientific discussion of trial results

Overall, 100% of the study participants (18 of 18) reported antibody positivity to at least two vaccine antigens, and 94% (17 of 18) reported positivity to three antigens; 56% (10 of 18) were positive to all four antigens.

Similarly, a deeper ELISpot analysis of the T-cell immune data showed that 78% (14 of 18) subjects showed T-cell responses to at least one vaccine antigen, 72% (13 of 18) responded to at least two antigens, and 50% (9 of 18) responded to all four antigens. Moreover, analysis of T-cell immune data 24 weeks after the last immunization showed that the responses were still detectable in 86% of evaluable patients, indicating that T-cell responses, in addition to antibody responses, persist for at least 6 months after the final immunization at month 3.

The investigators also undertook a more detailed analysis of antigen specific cytotoxic T-lymphocyte (CTL/killer T-cell) activity in the CD8+ T-cells from the high dose cohort of vaccinated subjects by measuring the expression of biologic markers like granzyme B and perforin (proteins that are known to be important in killing) as well as the direct killing of cells displaying HPV antigens on their surface through the release of granzyme B from the CTLs. Results presented in the paper show that these patients showed a significant increase in the amount of granzyme B and perforin found within their CTLs, and direct killing by CTLs was observed in all vaccinated subjects (6 of 6) in the high dose cohort. These results suggest that immunization with VGX-3100 generated CD8+ T-cells that were capable of making granzyme B and perforin upon seeing HPV antigens, and that these CD8+ T-cells were able to effectively use the granzyme B and perforin to kill cells displaying HPV antigens on their surface – a clear indication of the presence of a functional CTL/killer T-cell response.

Phase II efficacy study on-going

Inovio continues patient recruitment for its phase II study of VGX-3100, which is designed to enroll 148 patients with cervical dysplasia at multiple study centers. This randomized, double-blinded, placebo-controlled study will assess regression of cervical lesions from CIN 2/3 or CIN 3 to CIN 1 or complete regression of the lesions. The secondary endpoint is to assess the clearance of HPV 16 or 18. Subjects will also be monitored for tolerability and safety. Inovio expects results from this trial late next year. See the HPV-003 clinical trial protocol.

About Cervical Dysplasias/Cancers

Human papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer. At any given time, approximately 10% of women worldwide are infected with HPV. While roughly 70% of HPV infections are cleared by the body on its own, persistent HPV can lead to dysplasia, or premalignant changes in cells, of the cervix. Researchers have estimated the global prevalence of clinically pre-cancerous HPV infections at between 28 and 40 million. Persistent dysplasias may then progress to cancer. Every year, 510,000 cases of cervical cancer are diagnosed worldwide, and about 288,000 of the afflicted women die.

Preventive vaccines such as GARDASIL® and CERVARIX® are playing an important role in limiting new HPV infections. However, preventive vaccines cannot provide protection for those already infected, which is a large population. In addition, a significant number of the girls and women eligible to be vaccinated are not receiving these preventive vaccines. There is no viable therapeutic vaccine or drug to treat HPV, nor dysplasias and cancers caused by HPV. Current ablative or surgical procedures to remove cervical dysplasias and cancers are unappealing due to their potential for disfigurement, the perceived negative impacts on childbirth, and the stress of the watch-and-wait approach that typically precedes these procedures.

HPV types 6, 11, 16 and 18 are responsible for 35% to 50% of the 1.4 million low-grade CIN 1 dysplasias diagnosed annually in the US. HPV types 16 and 18 are responsible for about 70% of the 300,000 high grade CIN 2/3 dysplasias as well as cervical cancer incidences.

About VGX-3100

Inovio’s VGX-3100 is designed to raise immune responses against the E6 and E7 oncogenes associated with HPV types 16 and 18, i.e. it targets four antigens. These oncogenes are responsible for transforming HPV-infected cells into pre-cancerous and cancerous cells. The goal is to stimulate a T-cell immune response strong enough to cause the rejection of these infected or transformed cells from the body. The potential of such a therapeutic vaccine would be to treat precancerous dysplasias (CINs), cervical cancers, as well as other cancers caused by these HPV types such as head and neck and anogenital cancers.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio’s proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio’s clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended June 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-449-4211, jrichardson@inovio.com

GREENESTONE (GRST) IMPLEMENTING ‘BUILD & BUY’ GROWTH STRATEGY

GREENESTONE IMPLEMENTING ‘BUILD & BUY’ GROWTH STRATEGY TO CAPITALIZE ON HUGE OPPORTUNITY IN BEHAVIORAL TREATMENT

GreeneStone Healthcare Corporation (OTCBB: GRST) (“GreeneStone” or “the Company”) announces that it will expand its addiction treatment facilities through a ‘build & buy’ growth strategy to take advantage of the green field opportunity in Canada and the ever growing demand in the US in the underserviced mental healthcare sector. GreeneStone aims to expand from its current 36-bed treatment capacity up to 300 beds over the next twenty four months. In the process, the company aims to expand its current revenue run rate of $7 million plus to nearly $90 million. Management has currently identified several potential acquisition opportunities in both the US and Canada, several of which include underperforming operations in the US and Canada and/or others that provide unique opportunity for profitable expansion.

GreeneStone is employing a ‘build & buy’ strategy in its growth plan. The company has established a successful ‘build’ track record. GreeneStone Muskoka was founded by converting a resort property into a first-class residential addiction treatment facility. The Company’s outpatient and aftercare treatment facility, GreeneStone Yorkville, successfully launched operations after the company identified and secured the property and hired the clinical team. The ‘buy’ portion of the expansion strategy is intended to expand the company’s breadth of services, currently consisting of inpatient addiction treatment, outpatient and aftercare service, and endoscopy procedures, along with eating disorders for which facilities have been secured and are in the process of being launched.

The company’s revenue generating capacity for treatment beds is currently in the range of $600 to $1000 per day per bed. Once GreeneStone’s next two clinics are opened, the company’s bed capacity will expand to 118 from its current 36-bed level, which would result in the company growing its revenues from the current $7 million annualized run rate to over $35 million. The revenue potential from expansion is considerable given the wide open playing field in Canada, and North America. Recent M&A activity in the sector has produced valuations for facilities in excess of $1,000,000 per bed, which would result in significant valuation expansion potential for the company and strong positioning in the current behavioral treatment sector.

“With awareness of mental health growing in North America, the healthcare market is only beginning to wake up to the serious need for service and the opportunity for companies to carve out an attractive niche in the sector. Rapidly building out bed capacity and related services is essential to establishing that positioning. Typical 300-500 bed players in this space have revenue run rates in excess of $100 million from those operations. We are highly active with our expansion strategy now and expect to be busy for quite some time in order to reach what we consider to be the sweet spot in terms of bed capacity starting at the 300 bed level,” commented Shawn Leon, CEO of GreeneStone Healthcare Corp.

GreeneStone is a new company in the behavioral treatment sector in Canada, an industry that has been well developed in the US but remains in its early evolutionary stages in Canada. With increased interest from private equity acquirers in recent history, the behavioral treatment sector has moved away from the periphery. Acquirers like Bain Capital and Elements Behavioral have clearly demonstrated the attractiveness of companies that can execute on the operational side in this underserviced market.

Follow GreeneStone Healthcare Corp. and the company’s activities at the following Facebook sites:

GreeneStone Muskoka: https://www.facebook.com/pages/GreeneStone-Muskoka/510641255628356

GreeneStone Yorkville: https://www.facebook.com/pages/GreeneStone-Yorkville/452197614820117

About GreeneStone Healthcare Corporation

GreeneStone Healthcare Corporation (OTCBB: GRST) is a provider of mental health services, specializing in the areas of addiction treatment, eating disorders, nutrition and weight loss, and executive healthcare. GreeneStone is among the many nascent healthcare companies re-defining the healthcare space for the modern economy, which include Roche Holding Ltd. (OTCQB: RHHBY), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Nektar Therapeutics (NASDAQ: NKTR), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Zogenix, Inc. (NASDAQ: ZGNX). The company operates medical and healthcare clinics in Ontario, Canada, serving a North American and international clientele. GreeneStone’s clinics meet several ends: (1) GreeneStone adds overflow capacity to an increasingly stretched public healthcare system in Canada, (2) GreeneStone mental health clinics provide private alternatives to publicly available but highly underserviced healthcare subsectors, and (3) GreeneStone meets newly developing healthcare needs undisturbed by the public/private market, such as eating disorders. The company is headquartered in Toronto, Canada.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as “expect,” “plan,” “will,” “may,” “anticipate,” “believe,” “should,” “intend,” “estimate,” and variations of such words. Forward-looking statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, those risks and uncertainties contained in this press release and those identified in the periodic reports that the company files with the Securities and Exchange Commission (the “SEC”) pursuant to the Exchange Act.

Investor information and email sign-up:

http://www.greenestoneinvestor.com

GlobalWise (GWIV) Announces New Channel Partnership With Level Seven

COLUMBUS, OH — (Marketwire) — 10/10/12 — GlobalWise Investments, Inc. (OTCBB: GWIV)(OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce a new channel partnership with Level Seven.

Level Seven (www.lvlsvn.com) (formally known as Stone Crossing) has over 30 years of experience integrating and implementing business process solutions. The company continuously pursues the next generation of software tools to provide competitive advantages to small, medium and enterprise customers. Level Seven focuses on solving clients’ business challenges by translating insight into relevant processes, content and experiences that are delivered, measured and optimized across channels, platforms and devices.

“The relationship with Level Seven will provide GlobalWise another expansive marketing channel for our cloud-based ECM software platform,” stated William “BJ” Santiago, CEO of GlobalWise. “Level Seven has a long and rich history in implementing complex business management software solutions that cross digital and traditional media. I am proud they have selected Intellivue™ to be added to their cloud-based software portfolio of services.”

Lisa Locklear, Business Development Director of Level Seven, stated, “Level Seven is thrilled to add the Intellivue™ suite to its offering. Enterprise Content Management offers a natural extension to the technology and business services that we provide to our clients. As a hosted service, Intellivue™ can also provide our clients with a value driven document management solution that requires minimal setup and training. The different hosting and workflow options that Intellivue™ offers will allow us to implement and scale based on what’s most important for each individual client and their budget.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

American Independence Corp. (AMIC) Announces 2012 Results

NEW YORK, Aug. 9, 2012 (GLOBE NEWSWIRE) — American Independence Corp. (Nasdaq:AMIC) today reported 2012 second-quarter and six-month results. This press release contains both GAAP and non-GAAP financial information for which reconciliations can be found at the end of this release.

Financial Results

Net income increased to $0.3 million ($.04 per share, diluted), for the three months ended June 30, 2012, compared to $0.1 million ($.02 per share, diluted), for the three months ended June 30, 2011. Revenues increased to $23.5 million for the three months ended June 30, 2012, compared to revenues of $22.0 million for the three months ended June 30, 2011, primarily due to an increase in premiums.

Net income increased to $1.4 million ($.17 per share, diluted), for the six months ended June 30, 2012, compared to $1.1 million ($.13 per share, diluted), for the six months ended June 30, 2011. Revenues increased to $45.7 million for the six months ended June 30, 2012, compared to revenues of $43.7 million for the six months ended June 30, 2011, primarily due to an increase in premiums.

The Company’s operating income^[1] for the three months ended June 30, 2012 was $0.6 million ($.08 per share, diluted), as compared to $0.1 million ($.02 per share, diluted) for the three months ended June 30, 2011. Operating income was $2.2 million ($.27 per share, diluted), for the six months ended June 30, 2012, as compared to $1.6 million ($.19 per share, diluted) for the six months ended June 30, 2011.

Chief Executive Officer’s Comments

Roy Thung, Chief Executive Officer, commented, “Net income increased this quarter primarily due to improved underwriting results in our fully insured segment. We continue to experience growth and improved loss ratio results in our stop-loss line from business underwritten by IHC Risk Solutions. We are now approved to write pet insurance in many key states, and look forward to recording premiums from this new line of business in the coming months. Our financial condition and balance sheet remain strong. We have no debt and have grown our book value to $11.59 per share at June 30, 2012 from $11.36 per share at December 31, 2011.”

Non-GAAP Financial Measures

The Company provides non-GAAP financial measures to complement its consolidated financial statements presented in accordance with GAAP: (i) Operating income is net income attributable to AMIC excluding non-cash charges related to the amortization of intangible assets recorded in purchase accounting, net realized investment gains (losses), and the federal income tax charge related to deferred taxes due to its federal net operating loss carryforwards, and (ii) Operating income per share is operating income (loss) on a per share basis. These non-GAAP financial measures are intended to supplement the user’s overall understanding of the Company’s current financial performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses that, when excluded from the GAAP results, may provide additional understanding of the Company’s core operating results or business performance. However, these non-GAAP financial measures are not intended to supersede or replace the Company’s GAAP results. A reconciliation of the non-GAAP results to the GAAP results is provided in the “Reconciliation of GAAP Income from Continuing Operations to Non-GAAP Income from Continuing Operations” schedule below.

About American Independence Corp.

AMIC, through Independence American Insurance Company and its other subsidiaries, offers major medical for individuals and families, medical stop-loss, small group major medical, short-term medical, and pet insurance. AMIC provides to the individual and self-employed markets health insurance and related products, which are distributed through its subsidiaries, Independent Producers of America, LLC and healthinsurance.org, LLC. AMIC markets medical stop-loss through its marketing and administrative company IHC Risk Solutions LLC.

Certain statements in this news release may be considered forward-looking statements, such as statements relating to management’s views with respect to future events and financial performance. Such forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, economic conditions in the markets in which AMIC operates, new federal or state governmental regulation, AMIC’s ability to effectively operate, integrate and leverage any past or future strategic acquisition, and other factors which can be found in AMIC’s other news releases and filings with the Securities and Exchange Commission. AMIC expressly disclaims any duty to update its forward-looking statements or earnings guidance, and does not undertake to provide any such guidance in the future.

^[1] Operating income is a non-GAAP measure and is defined as net income attributable to AMIC excluding non-cash charges related to the amortization of certain intangible assets recorded in purchase accounting, net realized investment gains and losses, and the federal income tax charge related to deferred taxes. The Company believes that the presentation of operating income may offer a better understanding of the core operating results of the Company. A reconciliation of income from continuing operations to operating income is included in this press release.

As of June 30, 2012 there were 8,272,332 common shares outstanding, net of treasury shares.

CONTACT: DAVID T. KETTIG
         (212) 355-4141 Ext. 3047
         www.americanindependencecorp.com

RiT (RITT) Announces Development of New High-Speed Indoor Wireless Optical Network

Patent-Pending Technology Will Replace Cumbersome Network Cables and Switches With State-of-the-Art Symmetrical, Bi-Directional Optical Links

Otelco (OTT) to Release 2012 Third Quarter Results

Otelco Inc. (NASDAQ: OTT)(TSX: OTT.un), a wireline telecommunication services provider in Alabama, Maine, Massachusetts, Missouri, New Hampshire, Vermont and West Virginia, today announced that it will release its 2012 third quarter financial and operational results after the close of trading on Tuesday, November 6, 2012. The Company will hold a conference call to discuss third quarter results on Wednesday, November 7, 2012, at 10:30 a.m. (Eastern Time). To listen to the call, participants should dial 719-325-2495 approximately 10 minutes prior to the start of the call. A telephonic replay will be available from 12:30 p.m. (Eastern Time) on November 7, 2012 through November 18, 2012 by dialing (719) 457-0820 and entering Confirmation Code 8646648.

The live broadcast of Otelco’s quarterly conference call will be available online at www.OtelcoInc.com or www.earnings.com on November 7, 2012, beginning at 10:30 a.m. (Eastern Time). The online replay will be available at approximately 12:30 p.m. (Eastern Time) and continue for 30 days.

ABOUT OTELCO

Otelco Inc. provides wireline telecommunications services in Alabama, Maine, Massachusetts, Missouri, New Hampshire, Vermont and West Virginia. The Company’s services include local and long distance telephone, network access, transport, digital high-speed data lines and dial-up internet access, cable television and other telephone related services. With approximately 100,000 voice and data access lines, which are collectively referred to as access line equivalents, Otelco is among the top 25 largest local exchange carriers in the United States based on number of access lines. Otelco operates eleven incumbent telephone companies serving rural markets, or rural local exchange carriers. It also provides competitive retail and wholesale communications services through several subsidiaries. For more information, visit the Company’s website at www.OtelcoInc.com.

Kingtone (KONE) Signed a Contract with Hualu Engineering & Technology

SEFE (SEFE) Finalizes Preparation for Balloon Testing Program

BOULDER, CO — (Marketwire) — 10/09/12 — SEFE, Inc. (OTCQB: SEFE) (OTCBB: SEFE) (the “Company”), a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, today announces the completion of preparations for its initial balloon testing program at the ranch test site in Laramie, Wyoming. The initial testing will focus on measuring the Thevenin equivalent power source available between the ground and atmosphere over a variety of altitudes and various air terminal configurations. SEFE has completed the FAA waiver application process and is implementing the requirements necessary to begin the tests.

The balloon testing program will aim to verify laboratory results for the collector development. Additionally, it is anticipated that the balloon testing program will deliver the first fully demonstrable prototype of SEFE’s Harmony III.

“Our balloon testing program and ranch test site will give us an invaluable platform to build out a fully operational Harmony III system in tandem with our continuous laboratory efforts,” stated SEFE Lead Scientist Ryan Coulson.

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

SEFE, Inc.
Justin Ackerman
714-495-1927
ir@sefelectric.com

Mission Investor Relations
404-941-8975
Investors@MissionIR.com

Targacept (TRGT) Takes Further Actions to Align Resources with Corporate Objectives

Targacept, Inc. (NASDAQ: TRGT) today provided details of a previously announced workforce reduction that will affect approximately 38% of current employees. The company further announced that it will close its laboratory operations by the end of 2012. Targacept is implementing these measures to align its resources more closely with corporate objectives that include realizing the value potential of its clinical programs and conserving capital to best position the company for future opportunities. The reduction in force and changes to operations are expected to generate annual savings of approximately $9.6 million beginning in 2013.

“This is a difficult step for us to take, as many talented professionals who have contributed significantly to Targacept over the years will be leaving the company. We are deeply appreciative of these employees for their years of committed service,” said Mark Skaletsky, Chairman of Targacept’s Board of Directors.

Targacept estimates one-time severance and other charges related to the reduction in force of approximately $1.5 million will be incurred in the fourth quarter of 2012. Targacept expects the actions announced today, together with steps implemented earlier this year, will generate annual savings of approximately $22.5 million on a going forward basis. Targacept currently has cash and investments of approximately $195.0 million and continues to expect that its cash resources will be sufficient to fund its operating requirements through at least 2015.

With the reduction in force announced today, Targacept will have 43 employees.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.

TARGACEPT
Building Health, Restoring Independence®

Forward-Looking Statements

This press release includes “forward-looking statements” made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, without limitation: the annual savings from the reduction in Targacept’s workforce and operational changes, alone or together with steps implemented earlier in 2012; the amount of severance and other costs related to the workforce reduction; the value potential of Targacept’s clinical-stage programs; or Targacept’s plans, expectations or future operations, financial position, revenues, costs or expenses. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including without limitation Targacept’s critical accounting policies and risks and uncertainties relating to: Targacept’s ability to implement the workforce reduction successfully and achieve the estimated savings; Targacept’s ability to manage its cash operating expenses; whether the workforce reduction will have an adverse impact on the development of any Targacept product candidate or Targacept’s business generally; the conduct and results of clinical trials and non-clinical studies and assessments of TC-5619, TC-5214, AZD3480, AZD1446 or any other Targacept product candidate, including the performance of third parties engaged to execute such trials, studies and assessments; whether positive findings from any particular completed clinical trial of TC-5619 will be replicated in ongoing or any future clinical trials; Targacept’s ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings; and those risks and uncertainties described under the heading “Risk Factors” in Targacept’s most recent Annual Report on Form 10-K and in other filings that it makes with the Securities and Exchange Commission. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Targacept cautions you not to place undue reliance on any forward-looking statement.

In addition, any forward-looking statement in this press release represents Targacept’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Targacept disclaims any obligation to update any forward-looking statement, except as required by applicable law.

NNR Therapeutics™ and Building Health, Restoring Independence® are trademarks or service marks of Targacept, Inc. Any other service marks, trademarks and trade names appearing in this press release are the properties of their respective owners.

NeoStem (NBS) Announces Very Small Embryonic-Like Cells Publication

NEW YORK, Oct. 8, 2012 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE MKT:NBS), an emerging leader in the fast growing cell therapy market, announced today that data from its collaborative studies with the University of Michigan School of Dentistry further expands the therapeutic potential of its proprietary regenerative cell therapy product, “VSELS^TM” (very small embryonic-like stem cells), by demonstrating bone regeneration capabilities in a study published online ahead of print¹ in the journal Stem Cells and Development (DOI: 10.1089/scd.2012.0327). The paper highlights that human VSEL stem cells form human bone when implanted in the bone tissue of SCID mice.

VSELs are a population of stem cells found in adult bone marrow with potential regenerative properties similar to those of embryonic stem cells. NeoStem has shown that these cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what NeoStem believes to be a population of stem cells that have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative effects known to be associated with embryonic stem cells.

This published controlled study, funded by NIH and led by Dr. Russell Taichman, Major Ash Collegiate Professor and Co-Director of the Scholars Program in Dental Leadership Department of Periodontics & Oral Medicine, University of Michigan and Dr. Aaron Havens, Department of Orthodontics and Pediatric Dentistry at University of Michigan, involved isolating G-CSF mobilized VSEL stem cells from the blood of healthy donors and transplanting them into burr holes made in the cranial bones of SCID mice. After three months, it was observed that the implanted VSEL stem cells had differentiated into human bone tissue in the crania of the mice. Dr. Taichman stated, “I believe this work represents a true partnership between Industry and Academic Institutions. Our findings that VSEL cells can generate human bone in animals would not have been feasible without the help and vision that Dr. Denis Rodgerson and his team at NeoStem brought to the table. It was my privilege to have been a part of this collaborative effort, and I see the resulting data as a significant milestone in stem cell therapy development. It is truly inspiring.”

Dr. Robin Smith, Chairman and CEO of NeoStem, added, “This is very exciting data that we believe will be the foundation for future VSEL stem cell studies of bone regeneration in humans. We look forward to moving the development work from the laboratory into the clinic to develop a therapeutic stem cell product to enhance bone formation in humans.”

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC (“PCT”), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem’s most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack. Athelos Corporation (“Athelos”), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSEL^TM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s or its partners’ successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company’s ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company’s ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company’s clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company’s ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company’s ability to protect its intellectual property, (xi) the company’s ability to successfully divest its interest in Erye, and (xii) matters described under the “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company’s other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

(1) Human Very Small Embryonic-Like Cells Generate Skeletal Structures, In Vivo. Havens A., et al., Stem Cells and Development.

CONTACT: For more information on NeoStem, please visit www.neostem.com
         or contact:

         Trout Group
         Gitanjali Jain Ogawa, Vice President
         Phone: +1-646-378-2949
         Email: gogawa@troutgroup.com

Ascent Solar (ASTI) Announces Launch of www.EnerPlex.biz

Ascent’s First Consumer Focused Website

Ascent Solar Technologies, Inc. (NASDAQ:ASTI), a developer of state-of-the-art, flexible thin-film photovoltaic modules, announced today the launch of www.EnerPlex.biz, the official website of Ascent’s range of consumer products.

Victor Lee, Ascent’s President & CEO, stated, “We are extremely excited and proud to be able to bring EnerPlex directly to consumers via EnerPlex.biz; Ascent’s EnerPlex products represent the opportunity to fundamentally change the way consumers use both solar and advanced mobile battery products.”

Lee continued, “EnerPlex.biz will allow Ascent to share directly with consumers exciting new product developments such as EnerPlex for the Samsung Galaxy S III as well as the upcoming EnerPlex for iPhone 5 & other consumer products.”

Utilizing the company’s industry leading thin-film CIGS solar modules as well as advanced lithium-ion battery technology, EnerPlex cases are some of the thinnest and lightest battery cases available. EnerPlex for the iPhone 4, weighing less than 74 grams and with a depth of only 14mm, maintains the slim, sleek and industrial lines of the iPhone 4 & 4S.

About Ascent Solar Technologies, Inc.

Ascent Solar Technologies, Inc. is a developer of thin-film photovoltaic modules using flexible substrate materials that can transform the way solar power generation integrates into everyday life. Ascent Solar modules, which were named one of TIME Magazine’s 50 best inventions for 2011, can be directly incorporated into standard building materials, commercial transportation, automotive solutions, space applications, consumer electronics for portable power and durable off-grid solutions. More information can be found at www.ascentsolar.com.

Apple and iPhone are registered trademarks of Apple Inc.

Samsung and Galaxy S are registered trademarks of Samsung Electronics Co., Ltd.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,” “plan,” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission.

Alvarion® (ALVR) Connects 300 Smart Cities in Brazil, Tripling Deployments in Two Years

Alvarion^®Ltd. (NASDAQ: ALVR), a global provider of optimized wireless broadband solutions addressing the connectivity, coverage and capacity challenges of public and private networks, today announced that the company has deployed its best-in-class carrier-grade wireless broadband solutions in approximately 300 municipalities across 24 different states in Brazil, creating ‘Smart Cities’ dedicated to delivering superior services to residents and improving quality of life.

These ‘Smart Cities’ were built using Alvarion’s BreezeNET® B, BreezeACCESS VL® and WBS Wi-Fi solutions in the 2.4 GHz, 4.9 GHz, 5.4 GHz and 5.8 GHz frequencies, enabling a single unified wireless broadband network that supports a wide range of applications. Such applications include indoor and outdoor Internet access, classroom connectivity and e-learning, intelligent traffic and transportation control, video surveillance for public safety, online services for citizens and voice, video and data connectivity for government offices, hospitals and other service providers.

A prime example of a ‘Smart City’ in Brazil is Feira De Santana City in Bahia State, a city of 600,000 residents. Feira De Santana is using Alvarion’s solutions to advance educational services by connecting over 240 schools to the Internet, linking over 32,000 computers daily, and allowing children and their parents to connect to classroom materials from home. The city also deployed a highly secured private network to connect its public healthcare clinics, enabling medical records and patient information exchange between clinics.

“Over the past three years, Alvarion’s network has made it possible for us to deliver a variety of services ranging from city-wide public Internet access, video surveillance for public safety, e-learning and connectivity for municipal buildings, schools and healthcare clinics,” commented Doctor and University professor Tarcízio Pimenta Júnior, mayor of Feira De Santana City in Bahia State, Brazil. “We use our wireless network in our work at City Hall as well as to provide valuable services to our residents. Deploying these services has allowed us to utilize our resources more efficiently, enhance our service level to our residents and greatly improve their quality of life.”

“Alvarion has extensive experience in ‘Smart City’ deployments, particularly in the Brazilian market where we’ve been active since 2006”, said Hezi Lapid, President and CEO of Alvarion. “Our best-in-class carrier-grade wireless broadband solutions are designed to deliver multiple applications, on the same network, with the highest standards of security and quality of service, allowing municipalities to build these wireless networks in an efficient and cost effective way.”

Alvarion’s solutions for ‘Smart Cities’ includes the BreezeNET® B solution, a comprehensive and highly-proficient portfolio of wireless point-to-point solutions for license-exempt frequency bands, the BreezeACESS® VL, a flexible and field-proven point-to-multipoint solution providing broadband wireless outdoor connectivity for a variety of voice, video and data applications in urban and rural deployments, and the carrier-grade Wi-Fi solutions, covering the legacy 802.11g (WBS Family) and the new 802.11n (WBSn Family) for outdoor and indoor environments.

“Our 300 deployments underscores the extent of our expertise and demonstrates our success in helping municipalities effectively use their resources to deliver more and better services to their citizens,” states Ricardo Pence, Director of Sales, Alvarion Latin America. “Our products are well positioned to help communities across Latin America bridge the digital divide and realize their full potential.”

Alvarion is participating in Brazil’s largest telecommunications show, Futurecom 2012, Rio de Janeiro, October 8-11, Pavilion 4, booth A8. To schedule a personal meeting please contact Latamd@alvarion.com.

Alvarion will host a presentation “Transform Your Great City into a Smart City” on Wednesday, October 10, 2012 at 6PM at the Sala Arpoador. At the presentation, Alvarion representatives will share their extensive experience in ‘Smart City’ deployments and feature existing and future ‘Smart City’ applications.

Follow us on Twitter

See us on LinkedIn

About Alvarion do Brasil

Alvarion launched is local operations in Brazil in the year 2000. Today the company has more than 1,000 trained certified engineers spread throughout the country working with more than 300 certified partners. Alvarion’s first ‘Smart City’ project in Brazil was the city of Catanduva in Sao Paulo State in 2006.

About Alvarion

Alvarion Ltd. (NASDAQ:ALVR) provides optimized wireless broadband solutions addressing the connectivity, coverage and capacity challenges of telecom operators, smart cities, security, and enterprise customers. Our innovative solutions are based on multiple technologies across licensed and unlicensed spectrums. (www.alvarion.com)

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Alvarion’s management and are subject to various factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: our failure to fully implement our 2012 turnaround plan, our inability to reallocate our resources and rationalize our business in a more efficient manner, potential impact on our business of the current global macro-economic uncertainties, the inability of our customers to obtain credit to purchase our products as a result of global credit market conditions, the failure to fund projects under the U.S. broadband stimulus program, continued delays in 4G license allocation in certain countries; the failure of the products for the 4G market to develop as anticipated; our inability to capture market share in the expected growth of the 4G market as anticipated, due to, among other things, competitive reasons or failure to execute in our sales, marketing or manufacturing objectives; the failure of our strategic initiatives to enable us to more effectively capitalize on market opportunities as anticipated; delays in the receipt of orders from customers and in the delivery by us of such orders; our failure to fully and effectively integrate the business and technology of Wavion Inc., acquired by us in November 2011, into our products and realize the expected synergies from the acquisition; the failure of the markets for our (including Wavion’s) products to grow as anticipated; our inability to further identify, develop and achieve success for new products, services and technologies; increased competition and its effect on pricing, spending, third-party relationships and revenues; our inability to establish and maintain relationships with commerce, advertising, marketing, and technology providers; our inability to comply with covenants included in our financing agreements; our inability to raise sufficient funds to continue our operations, either through equity issuances or asset sales; and other risks detailed from time to time in the Company’s annual reports on Form 20-F as well as in other filings with the U.S. Securities and Exchange Commission.

Information set forth in this press release pertaining to third parties has not been independently verified by Alvarion and is based solely on publicly available information or on information provided to Alvarion by such third parties for inclusion in this press release. The web sites appearing in this press release are not and will not be included or incorporated by reference in any filing made by Alvarion with the U.S. Securities and Exchange Commission, which this press release will be a part of.

You may request Alvarion’s future press releases by contacting Sivan Farfuri, sivan.farfuri@alvarion.com or +972.3.767.4333. Please see the Investor section of the Alvarion website for more information: http://www.alvarion.com/investors.

Alvarion®, its logo and certain names, product and service names referenced herein are either registered trademarks, trademarks, trade names or service marks of Alvarion Ltd. in certain jurisdictions. All other names are or may be the trademarks of their respective owners.

Vringo (VRNG) Files Lawsuit against ZTE

Vringo, Inc. (NYSE MKT: VRNG), a company engaged in the innovation, development and monetization of mobile technologies and intellectual property, today announced that its wholly-owned subsidiary, Vringo Infrastructure, Inc., filed a patent infringement lawsuit against the UK subsidiary of ZTE Corporation (ZTE). ZTE describes itself as “a leading global provider of telecommunications equipment and network solutions,” with recently reported annual revenue of US $13.7 billion (RMB 86.254 billion), according to filings with the Hong Kong Stock Exchange. According to ZTE’s public filings, the company generates its revenue primarily from the sale of telecommunications equipment and handsets.

“The filing of this action in the United Kingdom is an initial step in Vringo’s global licensing and enforcement program in the telecommunications sector. ZTE has elected not to take a license to patents in Vringo’s portfolio relevant to certain international standards, despite manufacturing and selling devices and equipment for a number of years that are said by ZTE to be compliant with those standards,” said David L. Cohen, Head of Licensing, Litigation, and Intellectual Property at Vringo. “We believe that ZTE is aware that it requires licenses to all patents that are essential to relevant standards. Further, we believe that ZTE is familiar with systems for declaring patents to standards-setting organizations and the relevant intellectual property rights policies for those organizations, having itself declared hundreds of patents to international standards.”

The lawsuit, filed in the UK High Court of Justice, Chancery Division, Patents Court, alleges infringement of European Patents (UK) 1,212,919; 1,166,589; and 1,808,029. Declarations have been filed at the European Telecommunications and Standards Institute (ETSI) that cover the patents. ZTE’s cellular network elements fall within the scope of all three patents, and ZTE’s GSM/UMTS multi-mode wireless handsets also fall within the scope of the ‘029 patent.

According to the complaint, Vringo is seeking a declaration that its patents have been infringed by ZTE’s activities and that the court use its full legal, equitable and injunctive power to stop ZTE’s activities as may be appropriate in the circumstances.

“ZTE’s liability will continue to increase as long as the issue remains unresolved. We hope that ZTE will work with us to resolve this matter in a positive and productive manner,” said Alexander R. Berger, Chief Operating Officer at Vringo.

A copy of Vringo’s complaint is available at www.vringoinc.com, and Vringo’s earlier correspondence to ZTE is available at http://1.usa.gov/OLWhDT.

About Vringo, Inc.

Vringo, Inc. is engaged in the innovation, development and monetization of mobile technologies and intellectual property. Vringo’s intellectual property portfolio consists of over 500 patents and patent applications covering telecom infrastructure, internet search, and mobile technologies. The patents and patent applications have been developed internally, and acquired from third parties. Vringo operates a global platform for the distribution of mobile social applications and services including Facetones® and Video Ringtones which transform the basic act of making and receiving mobile phone calls into a highly visual, social experience. For more information, visit: www.vringoIP.com.

Forward-Looking Statements

This press release includes forward-looking statements, which may be identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: the inability to realize the potential value created by the merger with Innovate/Protect for our stockholders; our inability to raise additional capital to fund our combined operations and business plan; our inability to monetize and recoup our investment with respect to patent assets that we acquire; our inability to maintain the listing of our securities on the NYSE MKT; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; potential competition from other providers and products; our inability to license and monetize the patents owned by Innovate/Protect, including the outcome of the litigation against online search firms and other companies; our inability to monetize and recoup our investment with respect to patent assets that we acquire; and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission (“SEC”), including our quarterly report on Form 10-Q filed with the SEC on August 14, 2012. Vringo expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Iteris (ITI) Selected for Two Five-Year Federal Highway Administration Contracts

Iteris, Inc. (NYSE MKT: ITI), a leader in providing intelligent traffic management solutions, has been selected to provide on-call task-order based services that the Federal Highway Administration (FHWA) will release under two contracts for a period of up to five years. Iteris will have the opportunity to compete, with a small group of other selected providers, on each task order as they are released by FHWA.

The two contracts for Support Services for the Office of Operations include: Operations and Intelligent Transportation Systems (ITS), and Traffic Incident and Events Management, and are valued at up to $67.6 million and $12.6 million, respectively.

“Our selection by FHWA as one of the lead contractors to bid on task orders as part of these prestigious and significant contracts is a testament to our strong relationship with FHWA, the expertise of our associates and our team, and the impact that intelligent traffic technologies can have on improving congestion,” said Abbas Mohaddes, president and CEO of Iteris. “We expect to be awarded several of the task orders over the five-year period and anticipate they will contribute to our revenues in a meaningful way.”

The scope of the Operations and ITS contract is expected to include support services for facilitating integrated ITS deployment through training and technical deployment and supporting the ITS and Connected Vehicle Research Programs. The scope of the Traffic Incident and Events Management award includes support services for traffic incident management, emergency transportation operations, and planned special events program areas.

About Iteris, Inc.

Iteris Inc. is a leader in providing intelligent information solutions to the traffic management market. The company is focused on the development and application of advanced technologies and software-based information systems that reduce traffic congestion, provide measurement, management and predictive traffic analytics, and improve the safety of surface transportation systems. By combining its patented products, decades of expertise in traffic management, and information technologies, Iteris offers a broad range of Intelligent Transportation System (“ITS”) solutions to customers worldwide. The firm is headquartered in Santa Ana, California, with offices nationwide and in the Middle East. For more information, please call 888-329-4483 or visit Iteris, Inc.. Also visit us on Facebook, Twitter, and You Tube.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This release may contain forward-looking statements, which speak only as of the date hereof and are based upon our current expectations and the information available to us at this time. Words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “should,” “could,” “may,” “will,” “can,” and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to win future task orders under these contracts and the impact of these contracts on our future revenues and operating results.

Important factors that may cause such a difference include, but are not limited to, our ability to win specific task orders and to specify, develop, and complete our technologies in a timely manner; budget constraints and changing governmental priorities; the timing and successful completion of task orders under these contracts; the potential unforeseen impact of product and service offerings from competitors and other competitive or governmental pressures; and the general economic, political, and specific conditions in the markets we address. Further information on Iteris, Inc., including additional risk factors that may affect our forward looking statements, is contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, and our other SEC filings that are available through the SEC’s website (www.sec.gov).

Separate Studies Distinguish Safety and Viability of Cytori’s (CYTX) Cell Therapy

– Separate Studies Distinguish Safety and Viability of Cytori’s Cell Therapy from Alternate Approaches –

Cytori Therapeutics (NASDAQ:CYTX) announced that three oral presentations related to its cell therapy are being presented today at the 10^th annual International Federation for Adipose Therapeutics and Sciences meeting. The findings provide insights into the mechanisms-of-action for Cytori’s cell therapy. One study identified high levels of micro-RNA (miRNA) markers in human tissue thought to play a role in the repair of tissue injury resulting from ischemia, or lack of blood flow. Two additional characterization and comparative analysis studies on human tissue reaffirmed cellular characteristics of Cytori’s cell therapy and distinguished the safety, viability and cell make-up as compared to cell outputs derived from alternate approaches.

“Results from all three studies have important implications for how the cells repair injured tissue and on the safety and viability of cell-based treatments derived from adipose tissue,” said John Fraser, Ph.D., Chief Scientist of Cytori Therapeutics. “Mechanisms identified in our miRNA analysis are consistent with our prior clinical and preclinical data, which suggest these mechanisms include angiogenesis, immune-modulation, and remodeling and wound repair. The miRNA study provides baseline data, which we can apply to our U.S. ATHENA clinical trial in refractory heart failure patients and other activities including our recently announced contract with BARDA for thermal burns.”

In one study, miRNA profiles were assessed in adipose-derived stem and regenerative cells (ADRCs) derived from human tissue samples. The purpose was to determine which miRNA markers are expressed, miRNA variability from patient to patient, cellular functions of miRNA, and to establish a baseline miRNA population on healthy patients to compare against patients with a specific disease. Specifically, miRNA markers associated with angiogenesis, tissue remodeling and wound repair, and modulation of the immune response were found to be highly represented in ADRCs.

“Our two additional characterization and comparative analysis studies evaluated alternate processing techniques and reaffirmed our proprietary enzyme-based process using Celution® is the clear gold standard,” added Dr. Fraser. “If the composition of a cell population extracted from adipose tissue by an alternative process is not equivalent to Cytori’s ADRC population, one cannot claim equivalence to ADRCs in terms of safety or efficacy in preclinical or clinical outcomes.”

The characterization and comparative analysis studies reaffirmed the high cell yield and viability as well as the heterogeneity in Cytori’s cell therapy approach. Cytori’s cells are derived with a proprietary formulation of clinical grade enzymes which break up the connective tissue and which are removed at the end of the process. Cytori’s cell mixture includes adipose-derived stem cells, based on the measure of colony forming units, and a high yield of CD34+ cells. By contrast, data in these studies showed that alternate approaches such as ultrasound or emulsification, contained little to no adipose-derived stem cells, a high concentration of red and white blood cells, and did not meet the key criteria for safe clinical use.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® system product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements including our ability to apply this data to our ATHENA study and other projects are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2011. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

Inovio Pharma (INO) Named Best Mid-Stage Product Development Company

BLUE BELL, Pa., Oct. 5, 2012  /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has been named Best Mid-Stage Product Development Company by the Philadelphia Business Journal as part of the Journal’s Life Sciences Awards, an annual program recognizing the region’s “medical miracle makers for their innovative approaches to improving the delivery of health care.” An independent panel of judges from leading companies and universities in the state selected the finalists.

Inovio was chosen by the Journal for “the accomplishments of a company that has important new therapies in the clinical trial stage of development.” This recognition was based on the biotech’s pipeline of synthetic preventive and therapeutic vaccines. Inovio is revolutionizing vaccines and is advancing a pipeline of innovative therapies and vaccines to treat or prevent HIV, cancer, influenza and other infectious diseases.

Inovio’s president and CEO, Dr. J. Joseph Kim, said, “Today’s award recognizes the clinical advances Inovio has made with three of our programs in phase II development. While we are proud of our accomplishments to date, we look forward to reaching our goal — to protect and treat people with a new generation of vaccines.”

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio’s proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio’s clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended June 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

Ur-Energy’s (URG) Lost Creek Project Now Fully Permitted Receives Record of Decision from BLM

LITTLETON, Colo., Oct. 5, 2012 /PRNewswire/ — Ur-Energy Inc. (TSX:URE, NYSE MKT:URG)  (“Ur-Energy” or the “Company”) is pleased to announce the receipt of the Record of Decision (ROD) from the Bureau of Land Management (BLM) approving the Plan of Operations for the Company’s Lost Creek uranium in-situ recovery (ISR) project in Wyoming, USA.  The ROD represents the final regulatory step needed by the Company to initiate construction and production operations at the project site.

(Logo: http://photos.prnewswire.com/prnh/20110913/LA67628LOGO)

“With the receipt of the Record of Decision, the activities at our Lost Creek ISR project will rapidly transition to facility construction and mine unit development,” said Jeff Klenda, Chairman of the Board of Ur-Energy. “Lost Creek is our Company’s premier project.  The next several months will be a very exciting period for Ur-Energy as we grow from a company conducting exploration and development activities to emerge as a viable Wyoming-based uranium production company.  I anticipate the Lost Creek mine becoming an important contributor to South-Central Wyoming’s economic development and employment opportunities for many years to come.”

Facility construction will start this month at the Lost Creek Project site.  During the next six to nine months, the Company will invest 30 to 40 million dollars in the project, located in Sweetwater County, Wyoming.  First production from Lost Creek is forecast for early summer of 2013.  The project is currently expected to produce more than seven million pounds of uranium yellowcake (U₃0₈) at a designed rate of one million pounds per year.

Through a comprehensive regulatory review process, Ur-Energy has obtained all of the permits and licenses required to produce uranium at the Lost Creek Project site.  The US Nuclear Regulatory Commission issued its license in August 2011.  The State of Wyoming Department of Environmental Quality (WDEQ) approved a Permit to Mine in October 2011.  The Company received the necessary permit to install and operate Class I water disposal wells from the WDEQ and the US Environmental Protection Agency.  Those agencies also approved an aquifer exemption authorizing the Company to conduct injection activities in the production well fields.

“We appreciate the thoroughness of all the regulatory agencies throughout the permitting process,” noted Wayne Heili, President and CEO of Ur-Energy.  “The comprehensive nature of the regulatory review process has included multiple opportunities for public input.  The efforts of the involved agency staffs have produced a foundation of permits and licenses on which we can build a model uranium recovery operation for the future of the Company.  My compliments go out to the regulatory community for their commitment to the values and mission of the agencies they represent.  I would also like to extend my appreciation to the multi-talented team at Ur-Energy for their dedicated efforts in achieving the completion of the permitting efforts for this project.”

About Ur-Energy
Ur-Energy is a junior uranium company currently completing mine planning and permitting activities to bring its Lost Creek Wyoming uranium deposit into production.  Permitting also will allow the construction of a two-million-pounds-per-year in situ uranium processing facility. Engineering for the process facility is complete and mine planning is at an advanced stage for the first two mine units. Ur-Energy engages in the identification, acquisition and exploration of uranium properties in both Canada and the United States. Shares of Ur-Energy trade on the Toronto Stock Exchange under the symbol “URE” and on the NYSE Amex under the symbol “URG”. Ur-Energy’s corporate office is located in Littleton, Colorado; its registered office is in Ottawa, Ontario.  Ur-Energy’s website is www.ur-energy.com.

FOR FURTHER INFORMATION, PLEASE CONTACT

This release may contain “forward-looking statements” within the meaning of applicable securities laws regarding events or conditions that may occur in the future (e.g., timing of construction and commencement of production at Lost Creek; the anticipated life of mine and recovery estimates of Lost Creek) and are based on current expectations that, while considered reasonable by management at this time, inherently involve a number of significant business, economic and competitive risks, uncertainties and contingencies. Factors that could cause actual results to differ materially from any forward-looking statements include, but are not limited to, capital and other costs varying significantly from estimates; failure to establish estimated resources and reserves; the grade and recovery of ore which is mined varying from estimates; production rates, methods and amounts varying from estimates; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; inflation; changes in exchange rates; fluctuations in commodity prices; delays in development and other factors. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained herein are based on the beliefs, expectations and opinions of management as of the date hereof and Ur-Energy disclaims any intent or obligation to update them or revise them to reflect any change in circumstances or in management’s beliefs, expectations or opinions that occur in the future.

Western C&G (WRN) Closes Private Placement of Flow-through Common Shares

VANCOUVER, Oct. 5, 2012 /PRNewswire/ – Western Copper and Gold Corporation (“Western” or the “Company”) (TSX:WRN) (NYSE MKT: WRN) is pleased to announce that it has closed the non-brokered private placement for 500,000 flow-through common shares announced on September 25, 2012 involving certain insiders of the Company at a price of $0.80 per share for gross proceeds of $400,000.

The private placement closed on October 4, 2012. Insiders of the Company purchased 480,000 shares of the private placement. In accordance with securities legislation currently in effect, the shares are subject to a hold period expiring on February 5, 2013.

The gross proceeds from this private placement, which is subject to final acceptance by the TSX, will be used to incur qualifying Canadian Exploration Expenses.

The Company did not file a material change report more than 21 days before the expected closing of the private placement as the details of the private placement and the participation therein by related parties of the Company were not settled until shortly prior to closing and the Company wished to close the private placement on an expedited basis for sound business reasons.

ABOUT WESTERN COPPER AND GOLD CORPORATION

Western Copper and Gold Corporation is a Vancouver-based exploration and development company with significant copper, gold and molybdenum resources and reserves.  The Company has 100% ownership of the Casino Project located in the Yukon Territory. The Casino Project is one of the world’s largest open-pittable gold, copper, silver and molybdenum deposits. For more information, visit www.westerncopperandgold.com.

On behalf of the board,

“Dale Corman”
F. Dale Corman
Chairman & CEO

Cautionary Disclaimer Regarding Forward-Looking Statements and Information

Certain of the statements and information in this press release constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws.  Forward-looking statements and information generally express predictions, expectations, beliefs, plans, projections, or assumptions of future events or performance and do not constitute historical fact.  Forward-looking statements and information tend to include words such as “may,” “expects,” “anticipates,” “believes,” “targets,” “forecasts,” “schedules,” “goals,” “budgets,” or similar terminology.  Forward-looking statements and information herein include, but are not limited to, statements with respect to the completion of the private placement and use of proceeds.  All forward-looking statements and information are based on Western Copper and Gold’s or its consultants’ current beliefs as well as various assumptions made by and information currently available to them.  These assumptions include, without limitation that regulatory approvals to the proposed private placement and proposed listings will be obtained in a timely manner. Although management considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.  Forward-looking statements and information are inherently subject to significant business, economic, and competitive uncertainties and contingencies and are subject to important risk factors and uncertainties, both known and unknown, that are beyond Western Copper and Gold’s ability to control or predict.  Actual results and future events could differ materially from those anticipated in forward-looking statements and information.  Important factors that could cause actual results to differ materially from the Company’s expectations include market prices, availability of capital and financing, general economic, market and business conditions, and timeliness of regulatory approvals. Examples of potential risks are set forth in Western Copper and Gold’s annual report most recently filed with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators as of the date of this press release.  Accordingly, readers should not place undue reliance on forward-looking statements or information.  Western Copper and Gold expressly disclaims any intention or obligation to update or revise any forward-looking statements and information whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

Identive (INVE) Announces New Management Appointments

Michael Ganzera Named Vice President Marketing & Communication; Markus Gyssler Joins as Managing Director, ID Solutions Germany

SANTA ANA, Calif. and ISMANING, Germany, Oct. 4, 2012 (GLOBE NEWSWIRE) — Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV), a provider of products and services for the identification, security and RFID industries, today announced that it has streamlined and strengthened its management team with two new appointments.

Michael Ganzera has been tapped for the newly created corporate role of vice president Marketing & Communication. Ganzera joined the Company in 2008 and most recently has served as vice president Marketing & Business Development for Identive’s Identification Products division. Ganzera’s professional background includes 13 years in management roles within the smart card, contactless and payment industries. Prior to Identive, Ganzera held a variety of senior positions in engineering, product management, marketing and business development with NXP Semiconductors’ Identification Products Group. Ganzera’s education includes a Master’s degree in electrical engineering and broadcasting from the Technical University of Graz in Austria. In his new, broader role Ganzera will have responsibility for refining, coordinating and communicating the Company’s strategies, solutions and capabilities to the marketplace.

Markus Gyssler has been named managing director, ID Solutions Germany, with responsibility for Identive’s Multicard and Payment Solutions businesses. In this role Gyssler will consolidate the capabilities of the Company’s existing teams and resources to unify ID systems and solutions activities in Germany. The combined Identive ID Solutions business will focus on expanding the Company’s engagement with smart city projects, multi-function ID card solutions and cashless payment systems.

Gyssler brings more than 15 years’ experience in senior roles in project management, marketing, sales, business development, finance and operations gained in a number of global technology companies within the software, hardware and digital media industries. Prior to joining Identive, Gyssler was with the Actano Group, a Zurich-based project management solutions firm, where he held a variety of senior management positions, including most recently managing director for the XPERTS consulting arm of Actano GmbH. Earlier in his career Gyssler served in senior management roles with BetaResearch GmbH, the technology center of the KirchGroup, heading the product management division and several other units within the pay-TV sector. He holds a degree in Mechanical Engineering from the Technical University Munich and an MBA from the University of California at Berkeley.

“I am thankful for the commitment and hard work of Achim Hirz and Juergen Mueller who have recently departed the Company, and I am pleased to welcome Markus Gyssler to Identive in this important new role. Since its acquisition in early 2012, clear synergies have emerged between payment solution and our existing Multicard business, and we believe Markus will help to propel this process forward,” stated Ayman S. Ashour, chairman and chief executive officer of Identive. “As we continue to consolidate our various brands under Identive, Michael Ganzera’s experience in global communication and deep technological know-how makes him the ideal choice to broaden the awareness and acceptance of the Identive brand in the marketplace.”

About Identive

Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV) is focused on building the world’s signature company in Secure ID. The company’s products, software, systems and services address the markets for identity management, physical and logical access control, cashless payment, NFC solutions and a host of RFID-enabled applications for customers in the government, enterprise, consumer, education and healthcare sectors. Identive’s mission is to build a lasting business of scale and technology based on a combination of strong technology-driven organic growth and disciplined acquisitive expansion. The company delivers up-to-date information on its activity as well as industry trends through its industry-leading social media initiatives and educational resource, AskIdentive.com. For additional information, please visit www.identive-group.com or follow on Twitter at @IdentiveGroup.

The Identive Group, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8072

CONTACT: Darby Dye, +1 949 553-4251
         ddye@identive-group.com
         Lennart Streibel, +49 89 9595-5195
         lstreibel@identive-group.com

Trunkbow (TBOW) Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Rule

Company has 180 days to regain compliance

Escalon® (ESMC) Sells Its Clinical Diagnostics Business to ERBA Diagnostics (ERB)

Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem (CUR) ALS Trial

ROCKVILLE, Md., Oct. 4, 2012 /PRNewswire/ — Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase I trial to test Neuralstem’s human spinal cord stem cells, NSI-566, in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), will update trial data at the American Neurological Association annual meeting on Monday, October 8th (http://www.aneuroa.org/i4a/pages/index.cfm?pageid=3311).  Dr. Feldman’s poster presentation, “Completion and Outcomes of Phase I Intraspinal Stem Cell Transplantation Trial for ALS,” will be up from 11:30-6:30. Dr. Feldman will be discussing the data between 5:30-6:30.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Dr. Feldman is the President of the American Neurological Association, as well as Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. Dr. Feldman is an unpaid consultant to Neuralstem.

About the Trial

The Phase I trial to assess the safety of Neuralstem’s spinal cord neural stem cells and intraspinal transplantation method in ALS patients commenced in January 2010, and consisted of 18 treatments in 15 patients. The trial was designed to follow a risk escalation paradigm. The first 12 patients were each transplanted in the lumbar (lower back) region of the spine, beginning with non-ambulatory and advancing to ambulatory cohorts.

The trial then advanced to transplantation in the cervical (upper back) region of the spine. The first cohort of three was treated in the cervical region only. In an amendment to the trial design, The Food and Drug Administration (FDA) approved the return of previously-treated patients to this cohort. Consequently, the last cohort of three patients received injections in the cervical region in addition to the lumbar injections they had received earlier. All injections delivered 100,000 cells, for a dosing range of up to 1.5 million cells. The last patient was treated in August, 2012.  The entire trial concludes six months after the final surgery.

About Neuralstem

Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.

SOURCE Neuralstem, Inc.

Escalon® Medical (ESMC) Sells Its Clinical Diagnostics Business

CollabRx (CLRX) Partners with Life Technologies in Molecular Diagnostics

CollabRx, Inc. (NASDAQ: CLRX) today announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies’ global cancer diagnostics development and its laboratory developed test services business. The agreement represents a major step forward by CollabRx in providing laboratories and next-generation sequencing (NGS) companies with meaningful insights into cancer.

“Molecular analysis, including genetic sequencing, is increasingly becoming an important part of the clinical management of cancer patients,” said James Karis, Co-CEO of CollabRx. “However, the sheer volume and complexity of genetic data that is being produced, particularly in the course of therapy development, is outpacing the ability of practicing physicians to stay current, and more importantly understand how to apply this genetic data in treating their patients.”

CollabRx, Inc., a data analytics company focused on genomics, bridges this knowledge gap using cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts.

Life Technologies will use CollabRx proprietary content and technology to pair the results of broad molecular profiling panels developed by Life Technologies with associated clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRx’s large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the “context engine” for informing healthcare decision-making.

“It’s critical to contextualize the results of complex cancer panels to make them useful for interpreting and treating physicians,” said Ronnie Andrews, president of Medical Sciences at Life Technologies. “CollabRx has pioneered the development of a scalable platform and process to provide actionable, accessible, and credible knowledge at the point of care to aid physicians in developing a cancer treatment plan based on tumor molecular profiles. We are excited to include this key capability with our molecular diagnostic tests.”

“As the genomics revolution continues to unfold, successful cancer diagnostic companies will need cutting-edge technologies as well as deep, personalized analytics,” said Thomas Mika, Co-CEO of CollabRx. “We are thrilled to be a part of Life Technologies’ strategy to establish a leadership position in the clinical diagnostics market by providing ordering physicians with clinically relevant interpretation of test results, personalized for each patient, as a seamless part of the reporting process via Web-based and mobile technologies.”

About CollabRx

CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

PHAZAR (ANTP) Appoints Robert E. Fitzgerald as President, CEO and Director

PHAZAR CORP, (NASDAQ: ANTP) today announced that Robert E. Fitzgerald has been appointed to serve as President, Chief Executive Officer and Director of the Company effective October 1, 2012. Mr. Fitzgerald’s current term as a director will expire at the Company’s next annual meeting of shareholders. Mr. Fitzgerald, of Fort Worth, Texas attended U.C.L.A and earned a degree in economics. Mr. Fitzgerald also attended U.C.L.A and received his Juris Doctorate.

Mr. Fitzgerald served as Chief Executive Officer of Proxim Wireless (fka YDI/Terabeam) from March, 1999 until February, 2008. Mr. Fitzgerald has also served as Consultant of Ubiquiti Networks from April, 2009 until August, 2010, including a portion as President. Mr. Fitzgerald is Chairman of the Board of SeeView Security Inc., a Director of Steely Eye, Ltd. and an officer and investor in a number of entities under the control or direction of QAR, LLC. Mr. Fitzgerald currently serves as President of QAR, LLC since February, 2008. QAR, LLC provides debt and equity capital to companies.

Mr. Fitzgerald replaces Mr. Garland P. Asher who resigned as President, Chief Executive Officer and Chairman of the Board of PHAZAR CORP and all positions of the subsidiaries of PHAZAR CORP on October 1, 2012. Mr. Asher served on the Board of Directors since 2008.

The Board of Directors of PHAZAR CORP appointed Gary W. Havener to serve as Chairman of the Board. Mr. Havener qualifies as an independent director as defined by NASDAQ Marketplace Rule 5605(a)(2).

Product information is available at www.antennaproducts.com and www.phazar.com.

The common stock of PHAZAR CORP is listed on the NASDAQ Capital Market under the trading symbol “ANTP”. This press release contains forward-looking information within the meaning of Section 29A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances and underlying assumption and other statements, which are other than statements of historical facts. Certain statements contained herein are forward-looking statements and, accordingly, involve risks and uncertainties, which could cause actual results, or outcomes to differ materially from those expressed in the forward-looking statements. The Company’s expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including without limitations, management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties, but there can be no assurance that management’s expectations, beliefs or projections will result, or be achieved, or accomplished.

Daegis (DAEG) Adds to Executive Team With Appointment of Anita Engles as VP

Daegis (NASDAQ: DAEG), a leading provider of eDiscovery software and services, announced today that Anita Engles has joined the company as Vice President of Product Marketing. In this role, Ms. Engles will lead product strategy, product marketing and quality assurance to execute Daegis’ strategic vision. Daegis leverages state-of-the-art technologies with eDiscovery services to meet the needs of corporations and law firms with innovative cost-saving solutions. This appointment rounds out a series of recent executive hires by Daegis.

Prior to joining Daegis, Ms. Engles served as Director of Product Management at CT Summation where she developed successful product and go-to-market strategies across a portfolio of litigation readiness and eDiscovery solutions. In addition to her work with CT Summation, Ms. Engles has deep experience developing product strategies and driving their execution across R&D, marketing, sales, technical services and operations for technology companies. Her expertise has landed her notable appointments including, most recently, Founder and Managing Director of AE Marketing, where she consulted with technology companies to develop products, business strategies and go-to market initiatives.

“Anita’s industry credentials are an ideal match for Daegis as we enter a period of rapid execution for our data-driven eDiscovery software,” said Deborah Jillson, President of Daegis. “We are in good hands with Anita. She is a valuable addition to our team, experienced at bringing innovative solutions to market while inspiring the teams she leads.”

“Daegis is a respected front-runner in the eDiscovery market; I’ve long admired the Company’s pairing of visionary software and technology with solid customer-oriented services offerings,” states Ms. Engles. “The company’s SaaS delivery of innovative data-driven solutions represents one of the most advanced technological approaches to eDiscovery and I’m proud to be part of the team that will evangelize and evolve our technologies and products.”

About Daegis

Daegis (NASDAQ: DAEG) is a leading provider of eDiscovery solutions. The Daegis eDiscovery Platform delivers comprehensive cost-saving solutions for corporations and law firms. Daegis’ technology is revolutionizing eDiscovery through Cross-Matter Management, which enables the retention and reuse of custodian data and attorney work product from one matter to the next, mitigating the risk of inconsistencies and reducing costs by avoiding repetitive steps throughout the eDiscovery lifecycle. For more information, visit www.daegis.com, www.ediscoverycalculators.com or follow us via our blog and Twitter at @daegis.

BIOLASE (BIOL) Receives FDA Clearance and CE Mark for Its EPIC 10™ Diode Soft Tissue Laser

IRVINE, CA — (Marketwire) — 10/03/12 — BIOLASE, Inc. (NASDAQ: BIOL), the world’s leading dental laser manufacturer and distributor, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and Conformité Européene (CE) Mark approval for its EPIC 10™ diode soft tissue laser. BIOLASE initiated commercial sales in the final days of the third quarter of 2012 throughout the European Union and in those Asian and Latin American countries that recognize the CE Mark. The Company received notification of clearance from the FDA on October 1, 2012, and immediately began offering the EPIC 10 for sale in the U.S.

Federico Pignatelli, Chairman and Chief Executive Officer, said, “We are extremely pleased to have received FDA clearance and the CE Mark for the EPIC 10, the next generation of our diode laser technology platform. These are very significant milestones for BIOLASE. It also marks the second FDA clearance received since the new management team was put in place under my leadership. With its superior technology and design features, and total suite of treatment offerings, we expect that the EPIC 10 will develop into a substantial revenue driver.”

Innovations include the evolution of ComfortPulse™, BIOLASE’s proprietary technology that allows dentists to precisely control the level of laser energy that penetrates the target tissue. ComfortPulse keeps patients more comfortable by avoiding pain-inducing heat buildup at the surgical site, which can also cause excessive tissue damage. ComfortPulse can reduce laser pulses to as little as a ten-millionth of a second, with longer periods of “off” time, which results in greater patient comfort.

“While the EPIC 10 became available to sell in a limited number of countries internationally only in the final days of the third quarter of 2012, BIOLASE enjoyed solid year over year and sequential growth in its core Waterlase™ products, enabling the Company to meet its previously stated financial guidance for the quarter. We are very pleased with the backlog we have generated internationally for the EPIC 10, as well as very strong domestic interest. We expect the EPIC 10 to make significant contributions to our revenue in the 2012 fourth quarter and beyond,” Pignatelli concluded.

Chief Technology Officer Dmitri Boutoussov, PhD, said, “This next generation diode soft tissue laser allows for cleaner cutting, superior hemostasis, improved patient comfort, and greater versatility. Further, the EPIC 10 features a revolutionary and intuitive applications-based user interface with a high-resolution touch screen pre-programmed with 15 of the most commonly performed soft tissue procedures, including Pain Therapy, which is a highly popular treatment in the dental community for addressing pain in the oral-maxillofacial region.”

About BIOLASE, Inc.
BIOLASE, Inc., the world’s leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company’s laser products incorporate approximately 290 patented and patent pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 20,100 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.

EPIC 10™, Waterlase™, and ComfortPulse™ are trademarks of BIOLASE, Inc.

For updates and information on Waterlase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

For further information, please contact Lisa Wilson of In-Site Communications, Inc. at 212-759-3929.

Lisa Wilson
In-Site Communications, Inc.

MEI Pharma (MEIP) Issued European Patent For Lead Mitochondrial Inhibitor Drug